Press Release / NEWS / IASO，IASO Bio，IASO Biotherapeutics，IASO Biopharma，CT103A， CAR-T， cell therapy，dual-targeted CAR-T

NEWS

212026-08

IASO Bio's Registration Application for FUCASO® (equecabtagene autoleucel) Accepted by Australia's TGA
302026-07

Umoja Biopharma announces United States clinical trial initiation of industry’s first known CD22-targeted In Vivo CAR-T Therapy, developed in collaboration with IASO Bio
132026-08

IASO Biotechnology Announces Acquisition of Singapore-Based Cell Therapy Company MediSix Therapeutics
182026-06

IASO Bio Announces NDA Approval of Equecabtagene Autoleucel by the Singapore Health Sciences Authority (HSA) for the Treatment of Relapsed or Refractory Multiple Myeloma, Marking a Key Milestone in International Commercialization
102026-04

IASO Bio Establishes International Partnership with Instituto Butantan to Develop Innovative Therapy for Hematological Cancer
242026-03

IASO Bio Has Received Clearance from Japan’s PMDA to Initiate Clinical Trial for CAR-T Therapy Equecabtagene Autoleucel in Second- or Third-Line Multiple Myeloma
082025-12

IASO Bio Presents Updated Results for Equecabtagene Autoleucel in High-Risk Newly Diagnosed Multiple Myeloma Patients at 2025 ASH
272025-11

IASO Bio Announces BLA Approval of Fucaso (Equecabtagene Autoleucel) by the Hong Kong Department of Health for the Treatment of Relapsed or Refractory Multiple Myeloma
292025-10

IASO Bio Partners with Korea's GC Cell to Bring CAR-T Therapy to Korea
222025-10

Blood Publishes Promising Results of IASO Bio's Anti-GPRC5D CAR-T RD118 in Relapsed/Refractory Multiple Myeloma

Copyright © 2023 南京驯鹿生物技术股份有限公司　　　　苏ICP备2021047135号　　　　 Privacy Policy　|　Terms of Use